期刊文献+

枸橼酸托法替布的合成工艺优化

Improved synthetic process of tofacitib citrate
原文传递
导出
摘要 目的在现有专利和文献的基础上对枸橼酸托法替布合成工艺进行优化。方法以(3R,4R)-1-苄基-N,4-二甲基哌啶-3-胺二盐酸盐和2,4-二氯-7H-吡咯并[2,3-d]嘧啶为起始原料,经过缩合、氢化、中和、酰化、成盐等反应得到枸橼酸托法替布,并对各步合成工艺进行优化。结果目标物的结构经MS、^(1)H-NMR确证,总收率为55.7%(以原料(3R,4R)-1-苄基-N,4-二甲基哌啶-3-胺二盐酸盐计),纯度为99.86%。结论优化后的合成路线具有收率较高、操作简便、节能环保、适合工业化生产等优势。 On the basis of existing patents and literatures,the synthesis process of tofacitib citrate was optimized.With(3R,4R)-1-benzyl-N,4-dimethylpiperidine-3-amine dihydrochloride and 2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine as the starting materials,the target compound was obtained by a series of reactions such as condensation,hydrogenation,neutralization,acy lation and salification,the synthesis process of each step was optimized.The structure of the target compound was confirmed by MS and^(1)H-NMR.The total yield was 55.7%with the purity of 99.86%(HPLC).The optimized synthetic route has the advantages of high yield,simple operation,energy saving and environmental protection,and is suitable for industrial production.
作者 蒋岩 郭春 JIANG Yan;GUO Chun(School of Pharmaceutical Engineering,Shenyang Pharmaceutical University,Shenyang 110016,China;Jiangsu Xingnuo Medicine Technology Co.,Ltd.,Xuzhou 221000,China)
出处 《中国药物化学杂志》 CAS 2023年第11期836-839,848,共5页 Chinese Journal of Medicinal Chemistry
关键词 枸橼酸托法替布 合成 工艺优化 tofacitinib citrate synthesis process optimization
  • 相关文献

参考文献1

二级参考文献11

  • 1Burmester GR, Blanco R, Schoeman CC, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial [J]. Lancet, 2013, 381 (9865): 451-460.
  • 2Brown Ripin DH, Abele S, Cai WL, et al. Development of a scaleable route for the production of cis-N-benzyl-3- methylamino-4-methylpiperidine [J]. Org Process Res Dev, 2003, 7(1) : 115-120.
  • 3Rao TS, Zhang C. Deuterated tasocitinib derivatives as Janus kinase 3 inhibitors and their preparation and use for the treatment and prevention of Janus kinase 3-mediated diseases: WO, 2010123919 EP]. 2010-10-28. (CA 2010, 153: 555186).
  • 4Cai WL, Colony JL, Frost H, et al. Investigation of practical routes for the kilogram-scale production of cis-3- methylamino-4-methylpiperidines [J]. Org Process Res Dev, 2005, 9(1): 51-56.
  • 5Yarlagadda BS, Pooran C. Preparation of piperidine derivatives as immune suppressant for the treatment of diseases associated with pathologic JAK3 activation: WO, 2010014930 [P]. 2010-02-04. (CA2010, 152: 215329).
  • 6Andrew BT, Edward FM, John MM. Synthesis of pyrrolo [2,3-d] pyrimidine compounds as inhibitors of protein kinases: WO, 0142246 P. 2001-06-14. (CA 2001, 135: 46193).
  • 7Gut RS, Michael H J, Margaret MT, et al. Process for preparation of piperidinylamino pyrrolo- pyrimidines from activated pyrrolopyrimidines and piperidinylamines: WO, 2007012953 [P]. 2007-02-01. (CA 2007, 146: 206328).
  • 8Flanagan ME, Blumenkopf TA, Brissette WH, et al. Discovery of CP-690,550: a potent and selective Janus Kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection [J]. J ivied Chem, 2010, 53 (24) : 8468-8484.
  • 9Jiang JK, Ghoreschi K, Deflorian F, et al. Examining the chirality, conformation and selective kinase inhibition of 3- ((3R,4R) -4-methyl-3- (methyl (7H- pyrrolo [2,3- d] pyrimidin-4-yl) amino) piperidin- 1-yl) -3-oxopropanenitrile (CP-690,550) [J]. JMed Chem, 2008, 51 (24) : 8012-8018.
  • 10张建忠.2012年11月FDA批准新药概况[J].上海医药,2013,34(1):61-61. 被引量:5

共引文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部